Stereotactic Ablative Radiotherapy for Oligometastatic Breast Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the effectiveness of combining stereotactic ablative radiotherapy (SABR) with systemic therapy for patients with oligometastatic breast cancer (OMBC). Participants will be randomly assigned to receive either the combined treatment or systemic therapy alone as their first-line therapy. The primary goal is to determine if adding SABR improves progression-free survival compared to systemic therapy alone. Secondary objectives include evaluating overall survival, response rates, and quality of life, among other factors.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytological confirmed recurrent OMBC.
2. Age ≥18 years old.
3. OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT.
4. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease.
5. Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment.
6. Patients with local recurrence and OMBC must have a controlled local recurrence.
7. ECOG/WHO 0-2.
8. Life expectancy \> 6 months.
9. Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred).
10. Symptomatic bone metastases are allowed if ablative therapy can be delivered.
11. Adequate organ function for the planned treatment according to local guide-lines.
12. For patients with liver metastasis:

    * No cirrhosis or hepatitis
    * Hepatic function:

      * Total bilirubin level \< 3.0 x institutional ULN
      * ALT, AST, GGT, and alkaline phosphatase levels \< 3.0 x institutional ULN
      * Albumin \> 2.5 mg/dL
    * Metastasis not adjutant to stomach or small bowel.
13. For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of \> 60mL/min.
14. Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator.
15. Negative pregnancy test within 14 days prior to start of treatment\*.
16. If childbearing potential, willing to use an effective form of contraception\*.
17. No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix.
18. Signed informed consent and willingness to follow the trial procedures.

Exclusion Criteria:

1. \> 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included). Change due to toxicity allowed.
2. Oligometastases in brain.
3. Malignant pleural effusion or ascites.
4. Metastasis growth that involves \> 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit.
5. Unable to undergo imaging by either CT scan or MRI.
6. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance.
7. Pregnancy or breast-feeding.
8. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).

Where it's running

• Cork University Hospital
  Cork, Ireland Recruiting
• Bon Secours Cork In Partnership with UPMC Hillman Cancer Centre
  Cork, Ireland Recruiting
• St Luke's Radiation Oncology Network (SLRON) at St Luke's Hospital Dublin, St James Hospital Dublin and Beaumont Hospital Dublin
  Dublin, Ireland Recruiting
• University Hospital Galway (UHG)
  Galway, Ireland Recruiting
• Sheba Medical Center Institute of Oncology
  Tel Aviv, Israel Recruiting
• Azienda Ospedaliero - Universitaria Careggi
  Florence, Italy Recruiting

Study contacts

• Principal investigator: Barbro K Linderholm, MD, PhD — Sahlgrenska University Hospital, Gothenburg
• Study coordinator: Katarzyna Kulbacka-Ortiz, CTO
• Email: katarzyna.kulbacka-ortiz@vgregion.se
• Phone: +46721470685

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ctDNA-guided sequential anti-HER2 therapy with CNS prophylaxis for HER2-positive metastatic breast cancer

  This trial will test whether using regular ctDNA blood tests to guide stepping up or down sequential anti-HER2 treatments, together with local therapies and measures to protect the brain and spinal cord, can produce long-lasting remission for people with HER2-positive stage IV breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07459673

• Trastuzumab deruxtecan plus pertuzumab with proactive side-effect monitoring for first-line HER2-positive metastatic breast cancer

  This trial will try trastuzumab deruxtecan together with pertuzumab and digital tools to catch and manage side effects early in people starting first-line treatment for HER2-positive metastatic breast cancer.

  Recruiting at 12 sites Phase 2 SOLTI Breast Cancer Research Group · Villejuif and 26 other locations · NCT07371585

• Meaning-Centered Therapy for Latinos for adults with advanced cancer

  This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT07225309

• Immediate simulation-free SBRT for people with up to five metastatic tumors

  This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07079098

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

• Stereotactic ablative radiotherapy versus single‑fraction palliative radiotherapy for oligoprogressive metastatic cancer

  This trial will test whether stereotactic ablative radiotherapy (SABR) works better than single‑fraction palliative radiotherapy (8 Gy) for people with 1–5 oligoprogressive metastatic lesions to delay the need for next‑line systemic therapy and improve quality of life.

  Recruiting British Columbia Cancer Agency · Surrey, British Columbia · NCT06918951

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.